Functional/Serologic Test
3002
ABO and Rh
Testing for pretransfusion donor and patient compatibility and to assist in the diagnosis. USA test status: This is an In Vitro Diagnostic (IVD)/Standard Method test. This test uses a standard universally accepted method, which is applied across laboratories and has an established record of reliability and clinical validity.
2200
ABO and Rh - Transplant
Testing for donor and patient compatibility in the context of a organ or bone marrow transplant. USA test status: This is a laboratory developed test (LDT).
3024
ABO Antibody Titer
ABO antibody titration tests for the assessment of prognosis in ABO-incompatible hematopoietic stem cell transplantation or for decision-making in ABO-incompatible kidney transplantation. Based on results determined by IRL, additional tests may be required. USA test status: This is a laboratory developed test (LDT).
1298
ADAMTS13 Activity
This assay is measured by Fluorescence Resonance Energy Transfer (FRET) with a synthetic substrate. USA test status: This is a laboratory developed test (LDT).
1299
ADAMTS13 Antibody
The antibody assay detects IgG antibody serologically by ELISA. USA test status: This is a laboratory developed test (LDT).
1295
ADAMTS13 Evaluation
ADAMTS13 Evaluation is a reflexive testing algorithm for evaluation of TTP. Activity is always performed. If result is <= 30%, the inhibitor assay (1297) is performed. If inhibitor result is <= 0.7 Inhibitor Units, the antibody assay (1299) is performed. USA test status: This is a laboratory developed test (LDT).
1297
ADAMTS13 Inhibitor
The inhibitor assay measures antibodies that inhibit ADAMTS13 function by mixing study. USA test status: This is a laboratory developed test (LDT).
3060
Antibody Identification Workup
ABO/Rh, Direct Antiglobulin Test and one Ab ID. Based on results determined by IRL, additional tests may include selected cell panel(s), selected cell screens(s), rare cell panel(s), and pertinent antigen typing(s). USA test status: This is a laboratory developed test (LDT).
3080
Antibody Titration Workup
Detects the presence and measures the amount of antibodies within a person's blood. Monitoring antibody levels during pregnancy to help assess the risk of hemolytic disease of the fetus and newborn (HFDN). USA test status: This is a laboratory developed test (LDT).
3006
Antigen Typing - RBC (other than Rh)
USA test status: This is an In Vitro Diagnostic (IVD)/Standard Method test. This test uses a standard universally accepted method, which is applied across laboratories and has an established record of reliability and clinical validity.
1056
Anti-VWF Antibody IgG and IgM
This assay quantifies anti-VWF antibodies IgG and IgM using an ELISA plate method to support diagnosis of acquired von Willebrand disease. USA test status: This is a laboratory developed test (LDT).
3997
Autoimmune Hemolytic Anemia
Serologic testing to determine if patient's hemolytic anemia is caused by antibodies directed against the person's own red blood cells (RBCs). Refer to order test code #3060, Antibody Identification Workup, to request this baseline testing. If more comprehensive testing is desired, contact Versiti Client Services at 800-245-3117, ext. 6250. USA test status: This is a laboratory developed test (LDT).
3018
Complete Rh Phenotyping of RBCs
Includes: D, C, c, E, e antigens. USA test status: This is an In Vitro Diagnostic (IVD)/Standard Method test. This test uses a standard universally accepted method, which is applied across laboratories and has an established record of reliability and clinical validity.
2600
Crossmatch (Flow Cytometry)
The flow cytometric lymphocyte crossmatch is a technique for evaluating the compatibility of potential transplant recipients and donors and analyzed for the presence of bound IgG antibodies. USA test status: This is a laboratory developed test (LDT).
2610
Crossmatch (Flow Cytometry) Against Recipient
Recipient serum is incubated with donor lymphocytes which are analyzed in a flow cytometer for the presence of bound IgG antibodies to find donor-specific antibodies to avoid deleterious graft function. USA test status: This is a laboratory developed test (LDT).
2601
Crossmatch (Flow Cytometry) Titration
Titration allows you to determine the amount of antibody that gives you the best separation of populations in your samples, and the best measure of expression levels. USA test status: This is a laboratory developed test (LDT).
3111
DAT Negative Hemolytic Anemia Evaluation
Includes: ABO/Rh, Direct Antiglobulin Tests (including IgA detection), Elution (routine and enhanced), and antibody detection tests (routine and enhanced). Additional tests as necessary based upon results determined by Immunohematology Reference Lab. USA test status: This is a laboratory developed test (LDT).
3009
Direct Antiglobulin Test (DAT)
Also known as the direct Coombs test, is used primarily to help determine whether the cause of hemolytic anemia. USA test status: This is an In Vitro Diagnostic (IVD)/Standard Method test. This test uses a standard universally accepted method, which is applied across laboratories and has an established record of reliability and clinical validity.
3011
Donath-Landsteiner
Detects harmful antibodies related to a rare disorder called paroxysmal cold hemoglobinuria. Not available as an individual test. Requires initial evaluation at additional cost. USA test status: This is a laboratory developed test (LDT).
9500
Drug-Dependent Neutrophil Antibody
Test for antibodies in patient's serum that react against neutrophils only in the presence of a specific drug causing neutropenia. USA test status: This is a laboratory developed test (LDT).
9000
Drug-Dependent Platelet Antibody
This assay employs flow cytometric detection of drug-dependent platelet antibodies for several drugs. USA test status: This is a laboratory developed test (LDT).
3110
Drug-Dependent RBC Antibody Study
Evaluation of immune hemolysis after exposure to certain drugs is important in order to make the correct diagnosis and to prevent possible future adverse complications.Not available as an individual test. Requires initial evaluation at additional cost. USA test status: This is a laboratory developed test (LDT).
3020
Elution
Used for dissociating an antibody that is attached to the surface of a red blood cell. Used in identification of complicated antibodies, the workup of transfusion reactions or hemolytic disease of the newborn, and the workup of warm autoantibodies. USA test status: This is an In Vitro Diagnostic (IVD)/Standard Method test. This test uses a standard universally accepted method, which is applied across laboratories and has an established record of reliability and clinical validity.
1021
Factor II Activity
This assay measures activity of factor II. USA test status: This is a laboratory developed test (LDT).
1025
Factor II Inhibitor Profile
This order includes both Factor II Activity and Factor II Inhibitor. USA test status: This is a laboratory developed test (LDT).
1091
Factor IX Activity
This assay measures activity of factor IX. USA test status: This is a laboratory developed test (LDT).
1093
Factor IX Activity - Hepzyme Treated
This assay measures activity of factor IX, with addition of hepzyme to neutralize the influence of heparin. USA test status: This is a laboratory developed test (LDT).
1095
Factor IX Inhibitor Profile
This order set includes both Factor IX Activity and Factor IX Inhibitor. USA test status: This is a laboratory developed test (LDT).
1094
Factor IX Inhibitor Profile - Hepzyme Treated
This order set includes both Factor IX Activity and Factor IX Inhibitor, both including the addition of hepzyme to neutralize the influence of heparin. USA test status: This is a laboratory developed test (LDT).
1051
Factor V Activity
This assay measures activity of factor V. USA test status: This is a laboratory developed test (LDT).
1055
Factor V Inhibitor Profile
This order set includes both Factor V Activity and Factor V Inhibitor. USA test status: This is a laboratory developed test (LDT).
1071
Factor VII Activity
This assay measures activity of factor VII. USA test status: This is a laboratory developed test (LDT).
1075
Factor VII Inhibitor Profile
This profile includes: Factor VII Activity and Factor VII Inhibitor. USA test status: This is a laboratory developed test (LDT).
1135
Factor VIII Activity - Chromogenic
The chromogenic factor VIII activity assay uses bovine reagents, is insensitive to emicizumab and lupus anticoagulant, and is adversely affected by the presence of direct factor X inhibitors or high concentrations of heparin. USA test status: This is a laboratory developed test (LDT).
1081
Factor VIII Activity - Clot based
This test measures the activity of factor VIII to aid in diagnosis of hemophilia A, acquired factor VIII deficiency, or as part of diagnostic workup for von Willebrand disease (VWD). USA test status: This is a laboratory developed test (LDT).
1315
Factor VIII Activity - Concentrate
This test is used to determine the level of the coagulation protein Factor VIII in a vial of factor concentrate. USA test status: This is a laboratory developed test (LDT).
1310
Factor VIII Activity - Cryoprecipitate
This test is used to determine the level of the coagulation protein Factor VIII in a unit or pool of cryoprecipitate. Contact laboratory for additional information. USA test status: This is a laboratory developed test (LDT).
1136
Factor VIII Activity Hepzyme Treated - Chromogenic
The chromogenic factor VIII activity assay uses bovine reagents, is insensitive to emicizumab and lupus anticoagulant, and is adversely affected by the presence of direct factor X inhibitors or very high concentrations of heparin (greater than 2 U/mL). The addition of hepzyme in this assay will neutralize the influence of heparin. USA test status: This is a laboratory developed test (LDT). USA test status: This is a laboratory developed test (LDT).
1082
Factor VIII Activity Hepzyme Treated - Clot based
This assay measures activity of factor VIII, with addition of hepzyme to neutralize the influence of heparin. USA test status: This is a laboratory developed test (LDT).
1137
Factor VIII Inhibitor
The chromogenic factor VIII inhibitor assay uses bovine reagents, is insensitive to emicizumab and lupus anticoagulant, and is adversely affected by the presence of direct factor X inhibitors or high concentrations of heparin. USA test status: This is a laboratory developed test (LDT).
1138
Factor VIII Inhibitor - Hepzyme Treated
The chromogenic factor VIII inhibitor assay uses bovine reagents, is insensitive to emicizumab and lupus anticoagulant, and is adversely affected by the presence of direct factor X inhibitors or very high concentrations of heparin (greater than 2 U/mL). The addition of hepzyme in this assay will neutralize the influence of heparin. USA test status: This is a laboratory developed test (LDT).
1101
Factor X Activity
This assay measures activity of factor X. USA test status: This is a laboratory developed test (LDT).
1105
Factor X Inhibitor Profile
This order set includes: Factor X Activity and Factor X Inhibitor. USA test status: This is a laboratory developed test (LDT).
1111
Factor XI Activity
This assay measures activity of factor XI. USA test status: This is a laboratory developed test (LDT).
1115
Factor XI Inhibitor Profile
This order set includes: Factor XI Activity and Factor XI Inhibitor. USA test status: This is a laboratory developed test (LDT).
1121
Factor XII Activity
This assay measures activity of factor XII. USA test status: This is a laboratory developed test (LDT).
1125
Factor XII Inhibitor Profile
This order set includes: Factor XII Activity and Factor XII Inhibitor. USA test status: This is a laboratory developed test (LDT).
1011
Fibrinogen Activity
This assay measures fibrinogen activity. Versiti is temporarily unable to report a Fibrinogen Activity:Fibrinogen Antigen ratio or provide an interpretation when both the Fibrinogen Activity Assay (Order Code: 1011) and Fibrinogen Antigen Assay (Order Code: 1508) are ordered.USA test status: This is an In Vitro Diagnostic test (IVD).
1320
Fibrinogen Activity - Cryoprecipitate
This test is used to determine the level of the coagulation protein Fibrinogen in a unit or pool of cryoprecipitate. Contact laboratory for additional information. USA test status: This is a laboratory developed test (LDT).
1012
Fibrinogen Antigen - TEMPORARILY UNAVAILABLE
Effective October 23, 2023, and until we can validate a new in-house assay, any samples received for the Fibrinogen Antigen Assay (Order Code 1012) will be passed through, processed, and resulted by our send-out partner, ARUP. For information about the pass-through Fibrinogen Antigen Assay, refer to order code 1508. USA test status: This is a laboratory developed test (LDT).
1508
Fibrinogen Antigen - Plasma
Samples received for this assay are passed through, processed, and resulted by our send-out partner, ARUP. We are unable to hold or return samples, should you prefer your samples NOT be passed through. USA test status: This is a laboratory developed test (LDT).
5444
Glycoprotein IV (CD36) Typing
This assay utilizes flow cytometry in the typing of platelet glycoprotein IV (CCD36). USA test status: This is a laboratory developed test (LDT).
3100
Hemolytic Disease of the Newborn (HDN)
Serological analysis post-delivery to determine compatibility of mother and baby when Hemolytic Disease of the Newborn is suspected. USA test status: This is a laboratory developed test (LDT).
5514
Heparin-Dependent Platelet Antibody (PF4 ELISA) - IgA/M Panel
This Platelet Factor Four Enzyme Linked Immunosorbent Assay is designed for detection of Heparin-Dependent Platelet Antibodies of the IgM or IgA subclasses. USA test status: This is a laboratory developed test (LDT).
5510
Heparin-Dependent Platelet Antibody (PF4 ELISA) - IgG
This Platelet Factor Four Enzyme Linked Immunosorbent Assay is designed for detection of Heparin-Dependent Platelet Antibodies of the IgG subclass. USA test status: This is a laboratory developed test (LDT).
5502
Heparin-Induced Thrombocytopenia - PEA
This test is designed to detect heparin-dependent platelet antibodies in the serum from patients suspected of having Heparin-Induced Thrombocytopenia (HIT). USA test status: This is a laboratory developed test (LDT).
5508
Heparin-Induced Thrombocytopenia - SRA
This test is designed to detect heparin-dependent platelet antibodies in the serum from patients suspected of having Heparin-Induced Thrombocytopenia (HIT). USA test status: This is a laboratory developed test (LDT).
5509
Heparin-Induced Thrombocytopenia Evaluation (SRA)
Heparin-Induced Thrombocytopenia Evaluation is a reflexive algorithm. IgG-PF4 ELISA is always performed. If ELISA results are non-negative a Serotonin Release Assay will be performed. USA test status: This is a laboratory developed test (LDT).
5504
Heparin-Induced Thromobocytopenia Evaluation - PEA
USA test status: This is a laboratory developed test (LDT).
2235
HLA Antibody Detection (Flow Cytometry)
HLA antigen testing for solid organ and stem cell transplants. USA test status: This is a laboratory developed test (LDT).
2225
HLA Antibody Identification Class I Dilution- High Resolution
Detect HLA Class I antibodies. USA test status: This is a laboratory developed test (LDT).
2226
HLA Antibody Identification Class I High Resolution
Detect HLA Class I antibodies. USA test status: This is a laboratory developed test (LDT).
2230
HLA Antibody Identification Class II Dilution- High Resolution
Detect HLA Class II antibodies. USA test status: This is a laboratory developed test (LDT).
2231
HLA Antibody Identification Class II High Resolution
Detect HLA Class II antibodies. USA test status: This is a laboratory developed test (LDT).
5002
HOLD TRALI Recipient
Versiti Wisconsin, Inc will HOLD a recipient whole blood sample during TRALI donor testing. If an antibody is identified in the donor, the recipient sample could be genotyped to confirm presence of the target antigen by client's request.
5126
Neonatal Alloimmune Neutropenia (NAN) Panel - Father
This panel includes: Neutrophil Antigen Genotyping - HNA-1, 3, 4 and 5. USA test status: This is a laboratory developed test (LDT).
5125
Neonatal Alloimmune Neutropenia (NAN) Panel - Mother
This panel includes: Neutrophil Antigen Genotyping - HNA-1, 3, 4 and 5, and Neutrophil Antibody Identification and HLA Antibody Screen. USA test status: This is a laboratory developed test (LDT).
5703
Neonatal Alloimmune Thrombocytopenia (NAIT)-Initial Paternal
This order set includes: Platelet Antigen Genotyping Panel. To complete this workup, order Neonatal Alloimmune Thrombocytopenia (NAIT)-Initial Testing Maternal with Paternal (test code 5603) for maternal sample. USA test status: This is a laboratory developed test (LDT).
5303
Neonatal Alloimmune Thrombocytopenia (NAIT)-Initial Testing Maternal Only
This order set includes: Platelet Antigen Genotyping Panel and Platelet Antibody Identification Panel. Order this test when the father is not available for testing. USA test status: This is a laboratory developed test (LDT).
5603
Neonatal Alloimmune Thrombocytopenia (NAIT)-Initial Testing Maternal with Paternal
This order set includes: Platelet Antigen Genotyping on parents, Platelet Antibody Identification Panel on mother and maternal serum crossmatched with paternal platelets. To complete the workup, concurrently order NAIT-Initial Paternal (test code 5703) USA test status: This is a laboratory developed test (LDT).
5630
Neonatal Alloimmune Thrombocytopenia (NAIT)-Serial Monitoring Maternal only
This assay includes: Testing for antibodies against HPA-1a/b, HPA-2a/b, HPA-3a/b, HPA-4a, HPA-5a/b, GPIIb/IIIa, GPIa/IIa, GPIb/IX. GPIV and Class I HLA. USA test status: This is a laboratory developed test (LDT).
5640
Neonatal Alloimmune Thrombocytopenia (NAIT)-Serial Monitoring Maternal with Paternal
This order set includes: Platelet Antibody Identification Panel on mother and maternal serum crossmatched with paternal platelets. USA test status: This is a laboratory developed test (LDT).
5113
Neutrophil Antibody Identification and HLA Antibody Screen
This order set includes: Neutrophil Antibody Identification and HLA Antibody Detection. USA test status: This is a laboratory developed test (LDT).
5102
Neutrophil Antibody Screen
This flow-cytometry screen tests for the detection and identification of neutrophil antibodies. USA test status: This is a laboratory developed test (LDT).
5112
Neutrophil Antibody Screen and HLA Antibody Screen
This order set includes: Neutrophil Antibody Screen and HLA Antibody Detection. Automatic reflexing options are available. USA test status: This is a laboratory developed test (LDT).
5119
Neutrophil Antibody Screen with REFLEX to 5113 (Neut ID and HLA Screen)
This order will automatically reflex to Neutrophil Antibody Identification and HLA Detection if neutrophil reactive antibodies are detected. USA test status: This is a laboratory developed test (LDT).
5110
Neutrophil Antibody Screen with REFLEX to HLA Antibody Screen
This order will automatically reflex to HLA Detection if neutrophil reactive antibodies are detected. USA test status: This is a laboratory developed test (LDT).
3240
Partial RhD Analysis
Mutations in RHD may result in amino acid substitutions in the D protein. If those substances change the appearance or structure of exposed parts of the antigen on the outside of the RBC (epitopes), the patient is described as having partial D. USA test status: This is a laboratory developed test (LDT).
1175
Platelet Aggregation
Used to assess platelet function if a hereditary bleeding disorder is suspected. Includes: Aggregation with Ristocetin; Aggregation and ATP Release w/ ADP, Collagen, Thrombin and Arachidonic Acid. Platelets must be tested within four (4) hours of draw. To order testing, use the Platelet Aggregation Form USA test status: This is a laboratory developed test (LDT).
5608
Platelet Antibody Identification Panel
This panel includes: Testing for antibodies against HPA-1a/b, HPA-2a/b, HPA-3a/b, HPA-4a, HPA-5a/b, GPIIb/IIIa, GPIa/IIa, GPIb/IX, GPIV and Class I HLA. USA test status: This is a laboratory developed test (LDT).
5543
Platelet Antibody Screen
This assay screens patient sera for platelet-reactive antibodies via flow cytometry. USA test status: This is a laboratory developed test (LDT).
5544
Platelet Autoantibodies
This assay detects direct and indirect glycoprotein-specific antibodies in eluates prepared from washed patient platelets. USA test status: This is a laboratory developed test (LDT).
5545
Platelet Glycoprotein Expression (PGE)
This order includes: GPIb (Bernard Soulier Syndrome) and GPIIb/IIIa (Glanzmann Thrombasthenia). USA test status: This is a laboratory developed test (LDT).
5632
Platelet Transfusion Refractory (PTR) Panel
This panel includes: Platelet Antibody Identification Panel and Platelet Antigen Genotyping Panel. USA test status: This is a laboratory developed test (LDT).
5550
PNH - Erythrocytes and Leukocytes
Flow cytometric evaluation of both erythrocytes and leukocytes in evaluation for paroxysmal nocturnal hemoglobinuria (PNH). USA test status: This is a laboratory developed test (LDT).
5549
PNH - Leukocytes
Flow cytometric evaluation of leukocytes in evaluation for paroxysmal nocturnal hemoglobinuria (PNH). USA test status: This is a laboratory developed test (LDT).
1086
Porcine Factor VIII Inhibitor Profile
This order set includes both Factor VIII Activity-Clot based and Porcine Factor VIII Inhibitor. USA test status: This is a laboratory developed test (LDT).
1084
Porcine Factor VIII Inhibitor Profile - Hepzyme Treated
This order set includes both Factor VIII Activity-Clot based and Porcine Factor VIII Inhibitor, with addition of hepzyme to neautralize the influence of heparin. USA test status: This is a laboratory developed test (LDT).
5631
Post-Transfusion Purpura (PTP) Panel
Includes: Platelet Antibody Identification Panel and Platelet Antigen Genotyping Panel. USA test status: This is a laboratory developed test (LDT).
1031
Protein C Activity
This test provides the activity level of the blood coagulation factor, Protein C. This protein is one of the regulatory proteins in the blood clotting cascade. USA test status: This is an In Vitro Diagnostic test (IVD).
1033
Protein C Antigen
This test provides the antigen level of the blood coagulation factor, Protein C. This protein is one of the regulatory proteins in the blood clotting cascade. USA test status: This is a laboratory developed test (LDT).
1041
Protein S Activity
This test provides the activity level of the blood coagulation factor, Protein S. This protein is one of the regulatory proteins in the blood clotting cascade. USA test status: This is an In Vitro Diagnostic test (IVD).
1043
Protein S Antigen, Free
This test provides the antigen level of the blood coagulation factor, Protein S. This protein is one of the regulatory proteins in the blood clotting cascade. USA test status: This is an In Vitro Diagnostic test (IVD).
1042
Protein S Antigen, Total and Free
This test provides the antigen level of the blood coagulation factor, Protein S. This protein is one of the regulatory proteins in the blood clotting cascade. USA test status: This is an In Vitro Diagnostic test (IVD).
1068
Ristocetin-Induced Platelet Aggregation (RIPA)
Aggregation with high and low dose ristocetin is used to identify patients with type 2B von Willebrand Disease, platelet-type von Willebrand Disease or Bernard-Soulier Syndrome. To order testing, use the Platelet Aggregation Form USA test status: This is a laboratory developed test (LDT).
1260
Single Platelet Agonist Aggregation - ADP
Used to assess platelet function if a hereditary bleeding disorder is suspected. This test is used to determine how a patients platelets respond to the agonist ADP. Patients platelets must be tested within four (4) hours of draw. To order testing, use the Platelet Aggregation Form USA test status: This is a laboratory developed test (LDT).
1255
Single Platelet Agonist Aggregation - Arachidonic Acid
Used to assess platelet function if a hereditary bleeding disorder is suspected. This test is used to determine how a patients platelets respond to the agonist AA. Patients platelets must be tested within four (4) hours of draw. To order testing, use the Platelet Aggregation Form USA test status: This is a laboratory developed test (LDT).
1270
Single Platelet Agonist Aggregation - Collagen
Used to assess platelet function if a hereditary bleeding disorder is suspected. This test is used to determine how a patients platelets respond to the agonist collagen. Patients platelets must be tested within four (4) hours of draw. To order testing, use the Platelet Aggregation Form USA test status: This is a laboratory developed test (LDT).
1250
Single Platelet Agonist Aggregation - Thrombin
Used to assess platelet function if a hereditary bleeding disorder is suspected. This test is used to determine how a patients platelets respond to the agonist Thrombin. Patients platelets must be tested within four (4) hours of draw. To order testing, use the Platelet Aggregation Form USA test status: This is a laboratory developed test (LDT).
3021
Thermal Amplitude Study
Not available as an individual test. Requires initial evaluation at additional cost. USA test status: This is a laboratory developed test (LDT).
1850
VWD Diagnostic Panel
Reflexive algorithm always includes: FVIII Activity, VWF Antigen, VWF:GPIbM Activity, and VWF Collagen III Binding. Reflex testing may include: VWF Quantitative Multimer, VWF Propeptide Antigen, VWD Type 2N Binding and/or VWD Type 2B Binding. For patients <6 months of age, the ELISA-based VWF GPIbM Activity will be performed. For patients >/=6 months of age, Turbidimetric latex-based assay VWF GPIbM Binding Activity will be performed. VWF GPIbM Activity methodology cannot be changed upon request. USA test status for ELISA method: This is a laboratory developed test (LDT). USA test status for Turbidimetric latex-based method: This is an In Vitro Diagnostic test (IVD).
1230
VWD Therapeutic Monitoring
This panel includes Factor VIII Activity, VWF Antigen, and VWF GPIbM Activity. For patients <6 months of age, the ELISA-based VWF GPIbM Activity will be performed. For patients >/=6 months of age, our Turbidimetric latex-based assay VWF GPIbM Binding Activity will be performed. VWF GPIbM Activity methodology cannot be changed upon request. USA test status for ELISA method: This is a laboratory developed test (LDT). USA test status for Turbidimetric latex-based method: This is an In Vitro Diagnostic test (IVD).
1067
VWD Type 2B Evaluation
This order set includes VWD Type 2B Binding and VWD Type 2B Quantitative Multimer. USA test status: This is a laboratory developed test (LDT).
1089
VWD Type 2N Binding
This 2N-von Willebrand Disease panel is designed to distinguish type 2N-von Willebrand disease from mild hemophilia A and hemophilia A carriers. USA test status: This is a laboratory developed test (LDT).
1088
VWD Type 2N Profile
This order set includes: Factor VIII Activity, VWF Antigen and VWD Type 2N Binding. USA test status: This is a laboratory developed test (LDT).
1062
VWF Antigen
This assay measures a patient's total vWF protein level, independent of the multimer composition of the plasma. USA test status: This is a laboratory developed test (LDT).
1279
VWF Collagen Binding Profile
This assay tests the capacity of platelet adhesion at sites of blood vessel injury and can identify qualitative binding issues. Includes VWF Antigen, VWF Collagen III Binding, and VWF Collagen IV Binding. Additional reflex to VWF Quantitative Multimer, if indicated. USA test status: This is a laboratory developed test (LDT).
1281
VWF Collagen III Binding
This assay tests the capacity of platelet adhesion at sites of blood vessel injury and can identify qualitative binding issues. USA test status: This is a laboratory developed test (LDT).
1280
VWF Collagen IV Binding
This assay tests the capacity of platelet adhesion at sites of blood vessel injury and can identify qualitative binding issues. USA test status: This is a laboratory developed test (LDT).
1990
VWF GPIbM Activity Test
VWF GPIbM Activity is a ristocetin-independent activity assay and is an alternative to VWF Ristocetin Cofactor Activity with superior precision and sensitivity. VWF:GPIbM Activity, order code 1990, automatically applies the appropriate assay methodology based upon the patient's age at the time of sample collection. VWF GPIbM Activity methodology cannot be changed upon request. When the VWF GPIbM Activity is ordered, one of the following assays will be performed: (a) VWF GPIbM Activity performed by ELISA and is offered for patients <6 months of age. (b) VWF GPIbM Activity performed by Turbidimetric latex-based assay and is offered for patients >/=6 months of age. USA test status for ELISA method: This is a laboratory developed test (LDT). USA test status for Turbidimetric latex-based method: This is an In Vitro Diagnostic test (IVD).
1050
VWF Inhibitor Panel
Order set includes VWF Inhibitor Screen mixing study and VWF:GPIbM Activity. If the VWF GPIbM result is >/=50 IU/dL, the inhibitor screen is invalid and will be cancelled and credited. For patients <6 months of age, the ELISA-based VWF GPIbM Activity will be performed. For patients >/=6 months of age, our Turbidimetric latex-based assay VWF GPIbM Binding Activity will be performed. VWF GPIbM Activity methodology cannot be changed upon request. USA test status for ELISA method: This is a laboratory developed test (LDT). USA test status for Turbidimetric latex-based method: This is an In Vitro Diagnostic test (IVD).
1282
VWF Propeptide Antigen
This assay evaluates propeptide antigen levels. This result should be correlated with VWF antigen, VWF GPIbM, VWF multimers, and clinical history by the ordering physician to arrive at the appropriate diagnosis. USA test status: This is a laboratory developed test (LDT).
1063
VWF Quantitative Multimer
Quantitative multimer analysis provides an objective measure of VWF structure to characterize subtle changes observed in the subtypes of VWD and may help to determine the nature of any additional clinical laboratory testing to reach a clear-cut diagnosis. USA test status: This is a laboratory developed test (LDT).
3040
Weak RhD Analysis Workup
This complex test is ordered to resolve a Rh discrepancy (aka D antigen typing discrepancy). The molecular testing will identify Weak D Types 1, 2, and 3. These Weak D Types can be safely deemed Rh positive. USA test status: This is a laboratory developed test (LDT).